Alkermes (ALKS) Share-based Compensation (2010 - 2026)
Alkermes' (ALKS) quarterly Share-based Compensation came in at $31.1 million in Q2 2026, up 24.73% year-over-year from $25.0 million in Q2 2025, and up 98.16% quarter-over-quarter from $15.7 million in Q1 2026.
Analysis
Alkermes (ALKS) Share-based Compensation (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Share-based Compensation for 17 consecutive years, with $31.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Share-based Compensation rose 24.73% year-over-year to $31.1 million in Q2 2026; TTM through Jun 2026 was $73.8 million, a 8.68% decrease from a year earlier, with the FY2025 full-year figure at $98.7 million, up 2.15% from the prior year.
- Share-based Compensation was $31.1 million for Q2 2026 at Alkermes, up from $15.7 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $31.1 million in Q2 2026 and troughed at $622000.0 in Q3 2025.
- A 5-year average of $15.4 million and a median of $16.0 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 857.65% in 2025, down 88.73% in 2025.
- Over 5 years, Share-based Compensation stood at $3.3 million in 2022, then jumped by 683.12% to $25.8 million in 2023, then dropped by 19.72% to $20.7 million in 2024, then climbed by 26.64% to $26.3 million in 2025, then grew by 18.51% to $31.1 million in 2026.
- The last three Share-based Compensation figures came in at $31.1 million (Q2 2026), $15.7 million (Q1 2026), and $26.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.93 Bn | 625.17 Bn | 17.26 Bn | -950.00 Mn |
| 2 | AbbVie | 443.06 Bn | 436.49 Bn | 12.70 Bn | 166.00 Mn |
| 3 | Merck | 365.76 Bn | 358.62 Bn | 12.21 Bn | 298.00 Mn |
| 4 | Novartis Ag | 266.47 Bn | 258.78 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 249.00 Mn |
| 6 | Sanofi | 52.36 Bn | 44.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.97 Bn | 43.97 Bn | - | 277.20 Mn |
| 8 | Incyte | 25.42 Bn | 20.88 Bn | 1.57 Bn | 67.26 Mn |
| 9 | United Therapeutics | 21.52 Bn | 18.86 Bn | 683.80 Mn | 19.00 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 31.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.14 Mn |
| Mar 31, 2026 | 15.71 Mn |
| Dec 31, 2025 | 26.28 Mn |
| Sep 30, 2025 | 622,000.00 |
| Jun 30, 2025 | 24.97 Mn |
| Mar 31, 2025 | 29.53 Mn |
| Dec 31, 2024 | 20.75 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 2.61 Mn |
| Mar 31, 2024 | 11.23 Mn |
| Dec 31, 2023 | 25.84 Mn |
| Sep 30, 2023 | 23.92 Mn |
| Jun 30, 2023 | 9.13 Mn |
| Mar 31, 2023 | 2.87 Mn |
| Dec 31, 2022 | 3.30 Mn |
| Sep 30, 2022 | 26.05 Mn |
| Jun 30, 2022 | 16.20 Mn |
| Mar 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 19.02 Mn |
| Sep 30, 2021 | 25.60 Mn |